lenalidomide has been researched along with Minimal Disease, Residual in 50 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 19 (38.00) | 24.3611 |
| 2020's | 31 (62.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aquino, S; Beksac, M; Boccadoro, M; Bos, G; Broijl, A; Cafro, A; Cavo, M; Cornelisse, P; Croockewit, A; De Rosa, L; Dimopoulos, MA; Dozza, L; Driessen, C; Gay, F; Gregersen, H; Gulbrandsen, N; Hajek, R; Hveding, C; Levin, MD; Ludwig, H; Minnema, MC; Morelli, A; Offidani, M; Oliva, S; Palumbo, GA; Pantani, L; Pour, L; Sonneveld, P; Spencer, A; Troia, R; van de Donk, NWCJ; van de Velden, V; van der Holt, B; Waage, A; Wester, R; Wu, K; Ypma, PF; Zamagni, E; Zander, T; Zweegman, S | 1 |
| Bal, S; Callander, NS; Chhabra, S; Cornell, RF; Costa, LJ; D'Souza, A; Dhakal, B; Dholaria, BR; Giri, S; Godby, KN; Hall, A; Hardwick, P; Hari, P; Medvedova, E; Omel, J; Schmidt, TM; Silbermann, R | 1 |
| Cairns, DA; Cook, G; Davies, FE; de Tute, RM; Drayson, MT; Gregory, WM; Henderson, R; Hockaday, A; Jackson, GH; Jenner, MW; Jones, JR; Kaiser, MF; Menzies, T; Morgan, GJ; Owen, RG; Pawlyn, C; Rawstron, A | 1 |
| Bargay, J; Blade, J; Blanchard, MJ; Burgos, L; Calasanz, MJ; Cedena, MT; Cordon, L; de la Cruz, J; de la Rubia, J; Flores-Montero, J; Garcés, JJ; Hernandez, MT; Lahuerta, JJ; Martin, J; Martinez-Lopez, J; Martínez-Martinez, R; Mateos, MV; Orfao, A; Ortiol, A; Paiva, B; Perez, JJ; Puig, N; Rios, R; Rodriguez-Otero, P; Rosiñol, L; San-Miguel, JF; Sanoja-Flores, L; Sureda, A | 1 |
| Alessandria, B; Benedetti, F; Casaroli, I; Cascavilla, N; Castellino, C; Cortelazzo, S; De Luca, G; Drandi, D; Evangelista, A; Ferrante, M; Ferrero, S; Genuardi, E; Ghiggi, C; Ghislieri, M; Grimaldi, D; Hohaus, S; Ladetto, M; Liberati, AM; Mantoan, B; Musuraca, G; Pavone, V; Petrini, M; Re, F; Stefani, PM; Zaccaria, GM; Zanni, M | 1 |
| Anderson, LD; Derman, BA; Grinblatt, DL; Gurbuxani, S; Jakubowiak, AJ; Jasielec, J; Jiang, K; Kansagra, A; Karrison, T; Kin, A; Major, A; Narula, S; Rayani, S; Stefka, AT; Zonder, J | 1 |
| Matsue, K; Murata, R; Nakao, S; Takamatsu, H; Ueda, M; Yamashita, T; Yoroidaka, T; Yoshihara, K; Yoshihara, S | 1 |
| Bal, S; Callander, NS; Chhabra, S; Cornell, RF; Costa, LJ; D'Souza, A; Dhakal, B; Dholaria, BR; Giri, S; Godby, KN; Hall, AC; Hardwick, P; Hari, P; Medvedova, E; Omel, J; Schmidt, TM; Silbermann, R | 1 |
| Bargay, J; Blade, J; Blanchard, MJ; Burgos, L; Calasanz, MJ; Cedena, MT; Cordón, L; de la Cruz, J; de la Rubia, J; Flores-Montero, J; Garcia-Sanz, R; Gutierrez, NC; Hernandez, MT; Krsnik, I; Lahuerta, JJ; Lopez-Anglada, L; Maldonado, R; Martin, J; Martin-Ramos, ML; Martinez-Lopez, J; Martinez-Martinez, R; Mateos, MV; Moraleda, JM; Orfao, A; Oriol, A; Paiva, B; Palomera, L; Puig, N; Rios, R; Rosiñol, L; San-Miguel, JF; Sanoja-Flores, L; Sureda, A; Van Dongen, JJM; Vidriales, MB | 1 |
| Byrne, M; Chinratanalab, W; Cornell, RF; Culos, KA; Engelhardt, BG; Goodman, S; Gopalakrishnan, R; Jagasia, M; Kassim, AA; McArthur, E; Mosse, CA; Patel, DA; Savani, BN; Sengsayadeth, S | 1 |
| Dialoupi, I; Dimopoulos, MA; Eleutherakis-Papaiakovou, E; Fotiou, D; Gavriatopoulou, M; Kanellias, N; Kastritis, E; Kokkali, NA; Malandrakis, P; Migkou, M; Ntanasis-Stathopoulos, I; Papatheodorou, A; Roussou, M; Terpos, E | 1 |
| Chung, DJ; Diamond, B; Lesokhin, AM; Maclachlan, K; Ola Landgren, C | 1 |
| Lesokhin, AM; Wills, B; Wudhikarn, K | 1 |
| Diamond, B; Hillengass, J; Kazandjian, D; Landgren, CO; Maclachlan, K; Maura, F; Turesson, I | 1 |
| Dew, A; Hill, E; Kazandjian, D | 1 |
| Lu, SX | 1 |
| Kunacheewa, C; Manasanch, EE | 1 |
| Alonso, R; Bahri, N; Cedena, MT; Collado-Yurrita, L; García, C; Lahuerta, JJ; López-Jiménez, J; Martin, T; Martínez-López, J; Moraleda, JM; Ríos-Tamayo, R; Sánchez, R; Shah, N; Valeri, A; Wolf, J; Wong, S | 1 |
| Alameda, D; Alignani, D; Bargay, J; Blade, J; Burgos, L; Calasanz, MJ; Cedena, MT; Celay, J; Cordón, L; de la Rubia, J; Flores-Montero, J; Fresquet, V; Garcés, JJ; Garcia-Sanz, R; Goicoechea, I; Gutierrez, NC; Hernandez, MT; Krsnik, I; Lahuerta, JJ; Lara-Astiaso, D; Martin-Sanchez, J; Martinez-Climent, JA; Martinez-Lopez, J; Martinez-Martinez, R; Mateos, MV; Moraleda, JM; Orfao, A; Oriol, A; Paiva, B; Palomera, L; Puig, N; Ramos, MM; Rios, R; Rodriguez, I; Rodriguez, S; Rosiñol, L; San Miguel, J; Sarra, J; Sarvide, S; Vidriales, MB; Vilas-Zornoza, A | 1 |
| Anderson, LD; Chen, W; Fuda, FS; Gagan, J; Germans, SK; Jaso, JM; Koduru, P; Kulak, O; Oliver, D; Patel, P | 1 |
| Ahmed, Z; Anwer, F; Ashraf, A; Ehsan, H; Faisal, MS; Khakwani, M; Khan, A; Mushtaq, K; Rafae, A; Rehan, T; Shah, Z; Wahab, A | 1 |
| Bailly, C; Barbato, S; Boccadoro, M; Bodet-Milin, C; Caillot, D; Carlier, T; Cavo, M; Chauvie, S; Dozza, L; Fanti, S; Gallamini, A; Gamberi, B; Garderet, L; Gay, F; Karlin, L; Kraeber-Bodéré, F; Macro, M; Moreau, P; Nanni, C; Patriarca, F; Perrot, A; Sonneveld, P; Tacchetti, P; Versari, A; Zamagni, E | 1 |
| Bahlis, NJ; Duggan, P; Jimenez-Zepeda, VH; Lee, H; McCulloch, S; Neri, P; Tay, J | 1 |
| Amin, H; Avet-Loiseau, H; Bahlis, NJ; Casneuf, T; Chiu, C; Iida, S; Kobos, R; Krevvata, M; Lonial, S; Moreau, P; Plesner, T; Qi, M; Qin, X; Ramaswami, P; San-Miguel, J; Spencer, A; Sun, S; Trivedi, S; Ukropec, J; Usmani, SZ; Weisel, K | 1 |
| Derman, BA; Jakubowiak, AJ; Jasielec, JK; Jiang, K; Kubicki, T; McIver, A; Stefka, AT | 1 |
| Arcila, M; Chung, DJ; Derkach, A; Devlin, SM; Diamond, B; Dogan, A; Giralt, SA; Hassoun, H; Ho, C; Hultcrantz, M; Korde, N; Lahoud, O; Landau, H; Landgren, O; Lendvai, N; Lesokhin, A; Lu, S; Mailankody, S; Mastey, D; Roshal, M; Salcedo, M; Scordo, M; Shah, GL; Shah, U; Smith, EL; Tan, C; Tavitian, E; Werner, K | 1 |
| Attal, M; Belhadj, K; Benboubker, L; Caillot, D; Corre, J; Dupuis, J; Escoffre-Barbe, M; Facon, T; Garderet, L; Hébraud, B; Lauwers-Cances, V; Leleu, X; Manier, S; Mariette, C; Moreau, P; Roussel, M; Sonntag, C; Touzeau, C; Wuilleme, S | 1 |
| Bal, S; Costa, LJ | 1 |
| Arcila, ME; Chung, DJ; Derkach, A; Devlin, S; Diamond, B; Dogan, A; Giralt, SA; Hassoun, H; Ho, C; Hultcrantz, M; Korde, N; Lahoud, O; Landau, HJ; Landgren, O; Lesokhin, AM; Lu, SX; Maclachlan, K; Mailankody, S; Maura, F; Murata, K; Peterson, T; Ramanathan, L; Roshal, M; Rustad, EH; Scordo, M; Shah, GL; Shah, U; Smith, EL; Tan, C; Thoren, K | 1 |
| Boccadoro, M; Brandt-Hagens, C; Bruinink, DHO; Capra, A; Cavo, M; D'Agostino, M; Galli, M; Gay, F; Gilestro, M; Hajek, R; Jugooa, R; Offidani, M; Oliva, S; Omedé, P; Pantani, L; Petrucci, MT; Ribolla, R; Rihova, L; Sonneveld, P; Troia, R; van der Holt, B; van der Velden, VHJ; Villanova, T; Vsianska, P | 1 |
| Atenafu, EG; Gorospe, K; Liu, Q; Liyasova, M; Ma, B; McDonald, Z; Piza, G; Reece, D; Taylor, P; Trudel, S; Xu, X; Yang, L; Yao, C | 1 |
| Al-Sawaf, O; Aldaoud, A; Bahlo, J; Bosch, F; Böttcher, S; Döhner, H; Dörfel, S; Eichhorst, B; Fink, AM; Fischer, K; Ghia, P; Hallek, M; Hebart, H; Jentsch-Ullrich, K; Kater, AP; Kneba, M; Kreuzer, KA; Nösslinger, T; Ritgen, M; Robrecht, S; Stilgenbauer, S; Tausch, E; Wendtner, CM | 1 |
| Baldini, L; Benevolo, G; Boccadoro, M; Bringhen, S; Calafiore, V; Cerrato, C; Corradini, P; De Paoli, L; Falcone, AP; Gamberi, B; Guglielmelli, T; Hájek, R; Malfitano, A; Mannina, D; Mina, R; Musto, P; Nagler, A; Palumbo, A; Patriarca, F; Pescosta, N; Petrucci, MT; Ria, R; Spada, S; Spencer, A; Zambello, R | 1 |
| Anderson, KC; Arnulf, B; Attal, M; Avet-Loiseau, H; Belhadj, K; Benboubker, L; Brechignac, S; Carlton, V; Chretien, ML; Corre, J; Decaux, O; Dejoie, T; Dib, M; Doyen, C; Eveillard, JR; Facon, T; Faham, M; Fohrer, C; Garderet, L; Harousseau, JL; Hulin, C; Jaccard, A; Karlin, L; Kolb, B; Lauwers-Cances, V; Leleu, X; Macro, M; Maheo, S; Meuleman, N; Mohty, M; Moorhead, M; Moreau, P; Munshi, N; Pegourie, B; Perrot, A; Richardson, PG; Robillard, N; Royer, B; Stoppa, AM; Willis, T | 1 |
| Figg, WD; Hill, E; Kazandjian, D; Korde, N; Landgren, O; Mailankody, S; Roschewski, M | 1 |
| Bernardini, A; Boccadoro, M; Cavo, M; Conticello, C; Gambella, M; Gamberi, B; Gilestro, M; Grammatico, S; Larocca, A; Liberati, AM; Muccio, VE; Offidani, M; Oliva, S; Omedé, P; Palumbo, A; Rocci, A; Saraci, E; Sonneveld, P; Spada, S; Troia, R | 1 |
| Estey, EH; Percival, MM | 1 |
| Badoux, XC; Calin, S; Ferrajoli, A; Gao, H; Kantarjian, HM; Keating, MJ; Kornblau, SM; O'Brien, S; Reuben, JM; Strati, P; Wierda, WG | 1 |
| Nakaseko, C | 1 |
| Arthur, DC; Bhutani, M; Braylan, R; Burton, D; Calvo, KR; Carpenter, A; Carter, G; Choyke, P; Costello, R; Cunningham, SC; Faham, M; Figg, W; Gounden, V; Kazandjian, D; Kong, KA; Korde, N; Kurdziel, K; Kwok, M; Lamping, L; Landgren, O; Lindenberg, L; Mailankody, S; Manasanch, EE; Maric, I; Morrison, C; Mulquin, M; Peer, C; Roschewski, M; Sissung, TM; Steinberg, SM; Stetler-Stevenson, M; Tageja, N; Wall, Y; Weng, L; Wu, P; Yuan, C; Zhang, Y; Zingone, A; Zuchlinski, D | 1 |
| Alignani, D; Barcena, P; Barlogie, B; Blade, J; Burgos, L; Corchete, LA; De Arriba, F; Echeveste, MA; Epstein, J; García-Sanz, R; Gironella, M; Gonzalez, Y; Hernandez, MT; Johnson, SK; Lahuerta, JJ; Maiso, P; Mateos, MV; Ocio, EM; Orfao, A; Oriol, A; Paiva, B; Palomera, L; Puig, N; Rodriguez, I; San Miguel, JF; Sanchez, ML; Vidriales, MB | 1 |
| Cartron, G; Ceballos, P; Chopra, R; Cren, M; Duperray, C; Jourdan, M; Klein, B; Moreaux, J; Robert, N; Rossi, JF; Schafer, P; Vincent, L | 1 |
| Arana, P; Bargay, J; Bladé, J; Cabrera, C; Cedena, MT; Cordon, L; Echeveste, MA; Encinas, C; Flores-Montero, J; Gironella, M; Gonzalez, Y; Gutierrez, NC; Hernandez, MT; Lahuerta, JJ; Martin, J; Martín-Ramos, ML; Martinez, R; Martinez-Lopez, J; Mateos, MV; Ocio, EM; Orfao, A; Oriol, A; Paiva, B; Puig, N; Rosiñol, L; San Miguel, JF; Teruel, AI; Van Dongen, JJ; Vidriales, MB | 1 |
| Montefusco, V; Musto, P | 1 |
| Kovarikova, A; Kusenda, J | 1 |
| Bhutani, M; Burton, D; Calvo, KR; Carter, G; Costello, R; de Larrea, CF; Figg, WD; Gil, LA; Kazandjian, D; Korde, N; Kwok, M; Lamping, L; Landgren, O; Manasanch, EE; Maric, I; Mulquin, M; Roschewski, M; Steinberg, SM; Stetler-Stevenson, M; Tageja, N; Wu, P; Yuan, C; Zingone, A; Zuchlinski, D | 1 |
| Bernardini, A; Boccadoro, M; Caravita, T; Conticello, C; Drandi, D; Ferrero, S; Gambella, M; Gay, F; Genuardi, M; Gilestro, M; Liberati, AM; Muccio, VE; Musto, P; Oliva, S; Omedè, P; Palumbo, A; Passera, R; Patriarca, F; Pautasso, C; Pescosta, N; Petrucci, MT; Rocci, A; Saraci, E | 1 |
| Chen, W; Fan, L; Li, W; Liu, L; Liu, X; Xiong, B; Zou, P | 1 |
| Benson, DM; Crawford, BS; Efebera, Y; Elder, P; Hofmeister, CC; Mori, S; Phillips, G; Roddy, JV | 1 |
| Corradini, P; Farina, L; Rezzonico, F; Spina, F | 1 |
11 review(s) available for lenalidomide and Minimal Disease, Residual
| Article | Year |
|---|---|
Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future.
Topics: Adaptive Clinical Trials as Topic; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Glycine; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Thalidomide; Transplantation, Autologous; Withholding Treatment | 2020 |
Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action.
Topics: Antibodies, Bispecific; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Drug Administration Schedule; Humans; Immunoconjugates; Lenalidomide; Multiple Myeloma; Neoplasm, Residual; Recurrence; Survival Analysis; Thalidomide | 2020 |
Second malignancies in multiple myeloma; emerging patterns and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Neoplasm, Residual; Neoplasms, Second Primary; Risk Factors; Thalidomide; Transplantation, Autologous | 2020 |
The changing role of high dose melphalan with stem cell rescue in the treatment of newly diagnosed multiple myeloma in the era of modern therapies-back to the future!
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Risk Factors; Survival Analysis; Thalidomide; Transplantation, Autologous | 2020 |
Modern treatments and future directions for newly diagnosed multiple myeloma patients.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bortezomib; Clinical Trials as Topic; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Plasma Cells; Survival Analysis; Thalidomide; Transplantation, Autologous | 2020 |
High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Dexamethasone; Disease Progression; Drug Administration Schedule; Early Detection of Cancer; Humans; Lenalidomide; Monoclonal Gammopathy of Undetermined Significance; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Plasma Cells; Randomized Controlled Trials as Topic; Smoldering Multiple Myeloma; Survival Analysis | 2020 |
Lenalidomide-Associated Secondary B-Lymphoblastic Leukemia/Lymphoma-A Unique Entity.
Topics: Adult; Antineoplastic Agents; Bone Marrow; Cytogenetic Analysis; Fatal Outcome; High-Throughput Nucleotide Sequencing; Humans; Immunologic Factors; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Stem Cell Transplantation | 2020 |
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia.
Topics: Aminopyridines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Azacitidine; Cytogenetic Analysis; Decitabine; Enzyme Inhibitors; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Immunologic Factors; In Situ Hybridization, Fluorescence; Lenalidomide; Leukemia, Myeloid, Acute; Molecular Diagnostic Techniques; Neoplasm, Residual; Nivolumab; para-Aminobenzoates; Protein Kinase Inhibitors; Pyrazines; Pyrrolidines; Recombinant Fusion Proteins; Remission Induction; Transplantation, Homologous; Triazines; Triazoles | 2019 |
[Treatment of transplant-eligible symptomatic multiple myeloma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Combined Modality Therapy; Consolidation Chemotherapy; Cyclophosphamide; Dexamethasone; Drug Discovery; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Lenalidomide; Maintenance Chemotherapy; Melphalan; Multiple Myeloma; Neoplasm, Residual; Nitrogen Mustard Compounds; Pyrazines; Remission Induction; Thalidomide; Transplantation Conditioning | 2014 |
Are maintenance and continuous therapies indicated for every patient with multiple myeloma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multiple Myeloma; Neoplasm, Residual; Retreatment; Thalidomide; Treatment Outcome | 2016 |
Multiple myeloma, immunotherapy and minimal residual disease.
Topics: Antineoplastic Agents; Bortezomib; Combined Modality Therapy; Disease-Free Survival; Humans; Immunosuppressive Agents; Immunotherapy; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm, Residual | 2016 |
18 trial(s) available for lenalidomide and Minimal Disease, Residual
| Article | Year |
|---|---|
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Consolidation Chemotherapy; Dexamethasone; Europe; Humans; Lenalidomide; Maintenance Chemotherapy; Middle Aged; Multiple Myeloma; Neoplasm Staging; Neoplasm, Residual; Progression-Free Survival; Time Factors; Young Adult | 2021 |
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Oligopeptides | 2022 |
Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphoma.
Topics: Adult; Hematopoietic Stem Cell Transplantation; Humans; Kinetics; Lenalidomide; Lymphoma, Mantle-Cell; Neoplasm, Residual; Prospective Studies; Transplantation, Autologous | 2022 |
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Imides; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Proteasome Inhibitors | 2022 |
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Treatment Outcome | 2023 |
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boron Compounds; Bortezomib; Chromosome Aberrations; Dexamethasone; Drug Resistance, Neoplasm; Female; Flow Cytometry; Glycine; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Progression-Free Survival; Treatment Outcome | 2021 |
Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Transplantation, Autologous | 2021 |
Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Clinical Decision-Making; Dexamethasone; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Progression-Free Survival; Proof of Concept Study | 2021 |
Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results.
Topics: Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Survival Analysis; Treatment Outcome | 2021 |
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial.
Topics: Administration, Oral; Aged; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm, Residual; Progression-Free Survival | 2021 |
Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Bone Marrow Cells; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Flow Cytometry; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Male; Melphalan; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Survival Rate | 2021 |
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm, Residual; Survival Analysis; Thalidomide; Treatment Outcome | 2017 |
Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bortezomib; Dexamethasone; Disease-Free Survival; Female; Follow-Up Studies; High-Throughput Nucleotide Sequencing; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Plasma Cells; Survival Rate | 2018 |
Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Oligopeptides; Progression-Free Survival; Remission Induction; Treatment Outcome | 2018 |
Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Male; Neoplasm, Residual; Remission Induction; T-Lymphocytes; Thalidomide; Time Factors | 2013 |
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexamethasone; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Maryland; Middle Aged; Multiple Myeloma; National Institutes of Health (U.S.); Neoplasm, Residual; Oligopeptides; Pilot Projects; Proteasome Inhibitors; Risk Factors; Thalidomide; Time Factors; Treatment Outcome; United States | 2015 |
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.
Topics: Aged; Bortezomib; Cell Adhesion Molecules; Dexamethasone; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; Humans; Immunophenotyping; Integrins; Lenalidomide; Male; Melphalan; Models, Genetic; Multiple Myeloma; Neoplasm, Residual; Phenotype; Plasma Cells; Prednisone; Prognosis; Thalidomide | 2016 |
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Dexamethasone; Drug Monitoring; Female; Humans; Immunity; Lenalidomide; Male; Melphalan; Monitoring, Physiologic; Multiple Myeloma; Neoplasm, Residual; Prednisone; Prognosis; Survival Analysis; Thalidomide; Vincristine | 2016 |
21 other study(ies) available for lenalidomide and Minimal Disease, Residual
| Article | Year |
|---|---|
Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoplasm, Residual; Prognosis; Transplantation, Autologous; Treatment Outcome | 2022 |
Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dexamethasone; Humans; Lactate Dehydrogenases; Lenalidomide; Multiple Myeloma; Neoplasm, Residual; Neoplastic Cells, Circulating | 2022 |
Measurable Residual Disease Assessment Using Next-Generation Flow in Patients With Relapsed and Refractory Multiple Myeloma Treated With a Combination of Carfilzomib, Lenalidomide, and Dexamethasone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Humans; Lenalidomide; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm, Residual; Prospective Studies | 2023 |
Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Female; Flow Cytometry; Humans; Lenalidomide; Longitudinal Studies; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Randomized Controlled Trials as Topic | 2020 |
Minimal residual disease negativity and lenalidomide maintenance therapy are associated with superior survival outcomes in multiple myeloma.
Topics: Bortezomib; Disease-Free Survival; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoplasm, Residual; Treatment Outcome | 2020 |
Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Dexamethasone; Diphosphonates; Female; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Oligopeptides; Prospective Studies | 2020 |
Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma.
Topics: Humans; Lenalidomide; Multiple Myeloma; Neoplasm, Residual; Retrospective Studies; Treatment Outcome | 2020 |
Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Combined Modality Therapy; Dexamethasone; Doxorubicin; Forecasting; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Maintenance Chemotherapy; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm, Residual; Nervous System Diseases; Progression-Free Survival; Proteasome Inhibitors; Thalidomide; Transplantation, Autologous; Vincristine | 2020 |
Standardization of
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Female; Fluorodeoxyglucose F18; Humans; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Stem Cell Transplantation | 2021 |
The impact of COVID-19 in the management of AL amyloidosis and Immunoglobulin Deposition Disease: A single-center experience.
Topics: Aged; Alberta; Antibodies, Monoclonal; Basement Membrane; Bortezomib; COVID-19; COVID-19 Testing; Cyclophosphamide; Dexamethasone; Disease Management; Disease Susceptibility; Drug Therapy, Combination; Female; Humans; Immunoglobulin Light Chains; Immunoglobulin Light-chain Amyloidosis; Kaplan-Meier Estimate; Lenalidomide; Male; Methylprednisolone; Middle Aged; Neoplasm, Residual; Pandemics; Paraproteinemias; Precision Medicine; Retrospective Studies; SARS-CoV-2; Telemedicine | 2021 |
Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials, Phase III as Topic; Dexamethasone; Drug Resistance, Neoplasm; Humans; Lenalidomide; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm, Residual; Outcome Assessment, Health Care; Progression-Free Survival; Prospective Studies; Randomized Controlled Trials as Topic | 2021 |
Maintaining the minimal: dynamics of measurable residual disease with continuous lenalidomide therapy.
Topics: Dexamethasone; Disease-Free Survival; Humans; Lenalidomide; Multiple Myeloma; Neoplasm, Residual | 2021 |
A Personalized Mass Spectrometry-Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM).
Topics: Humans; Lenalidomide; Mass Spectrometry; Multiple Myeloma; Neoplasm Recurrence, Local; Neoplasm, Residual | 2021 |
Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Consolidation Chemotherapy; Female; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multicenter Studies as Topic; Multiple Myeloma; Neoplasm, Residual; Progression-Free Survival; Randomized Controlled Trials as Topic; Risk Factors; Stem Cell Transplantation; Time Factors; Transplantation, Autologous | 2018 |
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
Topics: Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Flow Cytometry; Humans; Immunologic Factors; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Real-Time Polymerase Chain Reaction; Risk Factors; Treatment Outcome | 2019 |
Differential effects of lenalidomide during plasma cell differentiation.
Topics: Antineoplastic Agents; Cell Differentiation; Cells, Cultured; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Multiple Myeloma; Neoplasm, Residual; Plasma Cells; Thalidomide | 2016 |
Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Dexamethasone; Enzyme Activation; Female; Humans; Immunoglobulin Isotypes; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Neoplasm Staging; Neoplasm, Residual; Oligopeptides; Proteasome Endopeptidase Complex; Thalidomide; Treatment Outcome | 2017 |
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Consolidation Chemotherapy; Disease Progression; Female; Humans; Lenalidomide; Maintenance Chemotherapy; Male; Middle Aged; Multiple Myeloma; Neoplasm, Residual; Prospective Studies; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2017 |
Efficacy of lenalidomide treatment and complete cytogenetic remission in a case of myelodysplastic syndrome with del(5q) and del(9q).
Topics: Aged; Angiogenesis Inhibitors; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 9; Female; Humans; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Neoplasm, Residual; Remission Induction; Thalidomide | 2010 |
Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Boronic Acids; Bortezomib; Combined Modality Therapy; Dexamethasone; Drug Monitoring; Drugs, Investigational; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunoglobulin G; Immunoglobulin kappa-Chains; Immunoglobulin lambda-Chains; Immunoglobulin M; Kaplan-Meier Estimate; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Myeloma Proteins; Neoplasm, Residual; Prognosis; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Thalidomide | 2012 |
Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia.
Topics: Adult; Antineoplastic Agents; Complementarity Determining Regions; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Neoplasm, Residual; Recurrence; Remission Induction; Thalidomide; Time Factors; Young Adult | 2013 |